Clinical Trial Update: ID93+GLA-SE Vaccine Against Tuberculosis in Older Adults Aged 55-74 [Phase 1]

View source ↗

Summary

Phase 1 clinical trial update for the ID93+GLA-SE vaccine targeting pulmonary tuberculosis in adults aged 55-74; the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• ID93 + GLA-SE vaccine

Snippet

Sponsor: Quratis Inc. | Conditions: Tuberculosis, Pulmonary | Phase 1 | Status: RECRUITING